CTLA4 and melanoma: As a result, CTLA-4 Nb-IL-2 and CTLA-4 Nb-Fc elicited more robust and sustained immune reactions in CD8+ T cells across hepatocellular carcinoma, breast cancer, and melanoma mouse models [140, 141].